Study drugs for certain FLT3-mutated blood cancers that have returned
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have one of these: FLT3-mutated AML, CMML, or a higher-risk MDS/MPN type
- Your cancer type is either relapsed/refractory (comes back/doesn’t respond) or newly diagnosed (depending on the trial group), and is in an intermediate-2 or high-risk category
- Your lab tests show an FLT3 mutation: either FLT3-ITD or a FLT3 D835 change
- Your general health is able to handle treatment (ECOG performance status 3 or better)
- Your blood and organ tests are adequate: bilirubin not too high, liver enzymes not too high, and kidney function (creatinine clearance) at least 30 mL/min
- You can swallow the study medicines and you are willing to sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests a combination of medicines (ASTX727, venetoclax, and gilteritinib) for adults with FLT3-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to see how well the treatment works and how safe it is for people whose disease has come back, is not responding, or (for some) is newly diagnosed.
This trial combines three drugs to treat certain types of leukemia or a related blood condition. It may be an option for people who cannot have standard intensive chemo, or for those whose disease has come back.
This trial tests a combination of two targeted drugs, SNDX-5613 and gilteritinib, for people whose AML has come back or hasn't responded to treatment. It is for those with an FLT3 gene mutation plus another specific genetic change like NPM1 or MLL. The study aims to see if this two-drug approach works better when used together.
This trial tests a combination of three drugs (revumenib, azacitidine, and venetoclax) for children and young adults with a hard-to-treat type of leukemia that has a specific genetic change. The goal is to see if this new mix can help when standard treatments have not worked.
This study tests a combination of two targeted drugs, gilteritinib and momelotinib, for people whose acute myeloid leukemia (AML) has returned or has not responded to standard treatment. The drugs aim to block signals that help leukemia cells grow, potentially offering a new option for those with a FLT3 mutation.
This trial is testing a combination of three drugs (FLAG-Ida, venetoclax, and asciminib) to see if it is effective and safe for people with certain types of leukemia (CML in blast phase or Ph+ AML) that are new or have come back after treatment. The goal is to see if this combination can control the disease and possibly lead to remission.
Hear when a new Recurrent Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.